<--- Back to Details
First PageDocument Content
Carbamates / Medicine / Lactams / Pefloxacin / B-cell chronic lymphocytic leukemia / Norfloxacin / Darunavir / Leukemia / Ofatumumab / Piperazines / Chemistry / Organic chemistry
Date: 2015-01-29 12:17:03
Carbamates
Medicine
Lactams
Pefloxacin
B-cell chronic lymphocytic leukemia
Norfloxacin
Darunavir
Leukemia
Ofatumumab
Piperazines
Chemistry
Organic chemistry

Add to Reading List

Source URL: www.accessdata.fda.gov

Download Document from Source Website

File Size: 836,01 KB

Share Document on Facebook

Similar Documents

Clinical medicine / Medicine / Breakthrough therapy / Cancer / B-cell chronic lymphocytic leukemia / Obinutuzumab / Ofatumumab / Ibrutinib / Rituximab / Leukemia / Idelalisib / Phosphoinositide 3-kinase inhibitor

Interim statement from the BCSH CLL Guidelines Panel George A Follows1, Adrian Bloor2, Claire Dearden3, Steve Devereux4, Christopher P Fox5, Peter Hillmen6, Ben Kennedy7, Helen McCarthy8, Nilima Parry-Jones9, Piers EM Pa

DocID: 1qeKO - View Document

Paragraph / Comparative Toxicogenomics Database / Ofatumumab / CD20 / Biology / Workflow / Science / Business / Typography / Writing / Workflow technology

Text mining workflow for extraction of paragraphs from full articles describing drug-gene interactions to support Onco KEM software platform for personalized treatments Fanny Perraudeau, David Morley, Mohammad Afshar, Ma

DocID: 1aeJg - View Document

Vorinostat / Cutaneous T-cell lymphoma / Ofatumumab / Medicine / Lymphoma / Hematopoietic stem cell transplantation

Legend Non-Hodgkin Lymphoma (NHL) Open to AccrualPh 2b Open-label, Randomized Two Arm Study of Selinexor plus Low

DocID: 18GfX - View Document

Carbamates / Medicine / Lactams / Pefloxacin / B-cell chronic lymphocytic leukemia / Norfloxacin / Darunavir / Leukemia / Ofatumumab / Piperazines / Chemistry / Organic chemistry

PDF Document

DocID: 17bbg - View Document

Genmab / Ofatumumab / Winkel /  North Holland

Q&A GENMAB 16. august 2012 Med CEO Jan Van de Winkel Transcript Live Q and A Genmab CEO Jan Van de Winkel, 16. august 2012 Akademikeren

DocID: 16VF9 - View Document